Q-omics provides the consensus-scored MSH4 profile across patient tissues and cancer cell-line models. MSH4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MSH4 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MSH4 RNA expression shows 16,328 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, KIRC, and THYM as cancer lineages where MSH4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSH4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSH4 survival associations across molecular data types. MSH4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSH4 RNA expression–survival associations across cancer types. High MSH4 expression shows unfavorable associations in LGG, KIRC, KIRP, LIHC and LUSC, but favorable associations in ACC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MSH4 RNA expression.
This table summarizes MSH4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MSH4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSH4 shows lower tumor expression in LUSC and HNSC and higher tumor expression in KIRC, LIHC, COAD and CHOL. The KIRC box plot shows higher MSH4 RNA expression in tumor versus normal tissue (log2 FC = +0.241, t-test p < 0.001).
This table shows molecular features associated with MSH4 in patient tissues and cancer cell lines. In patient samples, MSH4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSH4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Myeloma.
